二丁酰环磷腺苷钙不同给药途径治疗慢性心力衰竭的疗效比较  

Comparison of therapeutic effect of dibutyryl cyclic adenosine monophosphate calcium on chronic heart failure between different administration route

作　　者：肖文颖[1] 田松枚[1] 黄红漫[1] XIAO Wen-ying;TIAM Song-mei;HUANG Hong-man(Department of Cardiology,Shidong Hospital of Yang pu District of Shanghai City,Shanghai,200443,China)

机构地区：[1]上海市杨浦区市东医院心内科

出　　处：《心血管康复医学杂志》2019年第6期757-760,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：上海市医学重点专科建设项目(ZK2015B23);上海市卫生和计划生育委员会科研课题(201540298)~~

摘　　要：目的:比较二丁酰环磷腺苷钙(DCAMC)不同给药途径治疗慢性心力衰竭(CHF)的疗效。方法:98例CHF患者被随机均分为DCAMC静脉点滴组(静滴组)和DCAMC肌肉注射组(肌注组),两组患者均接受常规抗心衰治疗,疗程10d。观察比较两组治疗前后血浆N末端脑钠肽前体(NT-proBNP)水平、左室舒张末内径(LVEDd)、LVEF和不良反应情况。结果:与治疗前比较,两组治疗后血浆NT-proBNP水平[静滴组:(6846.23±3856.01)pg/ml比(2285.69±2023.79)pg/ml,肌注组:(6151.50±5160.09)pg/ml比(2568.37±2488.51)pg/ml]、LVEDd[静滴组:(4.78±0.44)cm比(4.69±0.43)cm,肌注组:(4.97±0.64)cm比(4.88±0.62)cm]均显著降低,LVEF[静滴组:(59.49±4.64)%比(60.67±4.52)%,肌注组:(57.67±7.19)%比(58.94±7.05)%]显著升高,P均=0.001。治疗前后,两组间上述指标差异均不显著,P均>0.05。两组间不良反应发生率无显著差异,P=1.000。结论:二丁酰环磷腺苷钙对于慢性心力衰竭的患者,能改善心功能,并且局部肌肉注射治疗能取得和静脉点滴治疗相同的临床疗效。Objective:To compare therapeutic effect of dibutyryl cyclic adenosine monophosphate calcium(DCAMC)on chronic heart failure(CHF)between different administration route.Methods:The 98 CHF patients were randomly and equally divided into intravenous drip(i.v.gtt)group and intramuscular injection group(i.m.)group,both groups received DCAMC via corresponding administration route based on routine anti heart failure treatment for 10d.Plasma level of N terminal pro brain natriuretic peptide(NT-proBNP),left ventricular end diastolic dimension(LVEDd),LVEF before and after treatment,and incidence of adverse reactions were observed and compared between two groups.Results:Compared with before treatment,there were significant reductions in plasma NT-proBNP level[i.v.gtt group:(6846.23±3856.01)pg/ml vs.(2285.69±2023.79)pg/ml,i.m.group:(6151.50±5160.09)pg/ml vs.(2568.37±2488.51)pg/ml]and LVEDd[i.v.gtt group:(4.78±0.44)cm vs.(4.69±0.43)cm,i.m.group:(4.97±0.64)cm vs.(4.88±0.62)cm],and significant rise in LVEF[i.v.gtt group:(59.49±4.64)%vs.(60.67±4.52)%,i.m.group:(57.67±7.19)%vs.(58.94±7.05)%]in two groups after treatment,P=0.001 all.There were no significant difference in above indexes between two groups before and after treatment,P>0.05 all.There was no significant difference in incidence rate of adverse reactions between two groups,P=1.000.Conclusion:DCAMC can improve cardiac function in CHF patients.Therapeutic effect of local intramuscular injection is equal with that of intravenous drip.

关 键 词：心力衰竭 环AMP 投药途径 

分 类 号：R541.61[医药卫生—心血管疾病]